UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma

PloS one, 2011-08, Vol.6 (8), p.e24167-e24167

2011

Volltextzugriff (PDF)

A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors

Clinical cancer research, 2015-03, Vol.21 (6), p.1281-1288

2015

Volltextzugriff (PDF)

RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy

Blood, 2004-03, Vol.103 (6), p.2046-2054

2004

Volltextzugriff (PDF)

Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk Neuroblastoma

Journal of clinical oncology, 2006-12, Vol.24 (36), p.5725-5734

2006

Volltextzugriff (PDF)

Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy

Breast cancer research and treatment, 2010-11, Vol.124 (1), p.1-11

2010

Volltextzugriff (PDF)

Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts

Molecular cancer therapeutics, 2009-06, Vol.8 (6), p.1484-1493

2009

Volltextzugriff (PDF)

Interferon-gamma-dependent infiltration of human T cells into neuroblastoma tumors in vivo

Clinical cancer research, 2009-11, Vol.15 (21), p.6602-6608

2009

Volltextzugriff (PDF)

Adaptive randomized phase II design for biomarker threshold selection and independent evaluation

Chinese clinical oncology, 2014-03, Vol.3 (1)

2014

Volltextzugriff (PDF)

Abstract IA21: Immune mobilizing TCR therapies against cancer (ImmTAC): A novel class of antigen-specific tumor immunotherapy

Cancer immunology research, 2016-11, Vol.4 (11_Supplement), p.IA21-IA21

Coughlin, Christina M.

2016

Volltextzugriff (PDF)

B7-1 and interleukin 12 synergistically induce effective antitumor immunity

Cancer research (Chicago, Ill.), 1995-11, Vol.55 (21), p.4980-4987

1995

Volltextzugriff (PDF)

Targeting Adult and Pediatric Cancers via Cell-Based Vaccines and the Prospect of Activated B Lymphocytes as a Novel Modality

Cancer biology & therapy, 2003-09, Vol.2 (5), p.466-470

2003

Volltextzugriff (PDF)

The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12

Cancer research (Chicago, Ill.), 1997-06, Vol.57 (12), p.2460-2467

1997

Volltextzugriff (PDF)

Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9521-9521

2018

Volltextzugriff (PDF)

A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.TPS269-TPS269

2020

Volltextzugriff (PDF)

Abstract 3655: Biomarker strategy to guide the clinical development of ImmTACTM molecules, a novel class of bispecific T cell engaging biologic drugs

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3655-3655

2017

Volltextzugriff (PDF)

A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.TPS347-TPS347

2019

Volltextzugriff (PDF)

Opportunities posed by novel patient selection biomarker approaches in oncology drug development: going beyond the cytotoxics

Biomarkers in medicine, 2008-04, Vol.2 (2), p.147-153

2008

Volltextzugriff (PDF)

Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.9531-9531

2017

Volltextzugriff (PDF)

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

Journal of clinical oncology, 2018-05, Vol.36 (13), p.1291-1299

2018

Volltextzugriff (PDF)

Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients with PIK3CA -altered and wild type ER+/HER2- locally advanced or metastatic breast cancer

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.PD5-5-PD5-5

2015

Volltextzugriff (PDF)

Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3016-3016

2016

Volltextzugriff (PDF)

Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis

The Journal of clinical investigation, 1998-03, Vol.101 (6), p.1441-1452

1998

Volltextzugriff (PDF)

Students in faith-based schools: An alternative path to the future or opting out of modernity?

Coughlin, Christina

2013

Volltextzugriff (PDF)

Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.590-590

2015

Volltextzugriff (PDF)

Abstract A35: Biomarker Strategy To Guide Clinical Development Of ImmTAC™ molecules , A Novel Class Of Bispecific T Cell Engaging Biologic Drugs

Cancer immunology research, 2017-03, Vol.5 (3_Supplement), p.A35-A35

2017

Volltextzugriff (PDF)

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(71)

Publikationsform

Sprache

Englisch
(83)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma

A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors

RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy

Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk Neuroblastoma

Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy

Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts

Interferon-gamma-dependent infiltration of human T cells into neuroblastoma tumors in vivo

Adaptive randomized phase II design for biomarker threshold selection and independent evaluation

Abstract IA21: Immune mobilizing TCR therapies against cancer (ImmTAC): A novel class of antigen-specific tumor immunotherapy

B7-1 and interleukin 12 synergistically induce effective antitumor immunity

Targeting Adult and Pediatric Cancers via Cell-Based Vaccines and the Prospect of Activated B Lymphocytes as a Novel Modality

The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12

Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings

A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer

Abstract 3655: Biomarker strategy to guide the clinical development of ImmTACTM molecules, a novel class of bispecific T cell engaging biologic drugs

A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer

Opportunities posed by novel patient selection biomarker approaches in oncology drug development: going beyond the cytotoxics

Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients with PIK3CA -altered and wild type ER+/HER2- locally advanced or metastatic breast cancer

Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma

Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis

Students in faith-based schools: An alternative path to the future or opting out of modernity?

Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)

Abstract A35: Biomarker Strategy To Guide Clinical Development Of ImmTAC™ molecules , A Novel Class Of Bispecific T Cell Engaging Biologic Drugs

Suchergebnisse filtern